|

Dapagliflozin in Active Lupus Nephritis

RECRUITINGPhase 4Sponsored by Brigham and Women's Hospital
Actively Recruiting
PhasePhase 4
SponsorBrigham and Women's Hospital
Started2026-05-19
Est. completion2029-07
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
Locations2 sites

Summary

Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* • Age 18-70 years, fulfilling 2012 SLICC or 2019 ACR/EULAR criteria for SLE, with biopsy-proven class III, IV and/or V LN

  * Active (new or relapsing) LN within the prior six months, with at least one of the following:

    * Kidney biopsy with activity index \>2 and/or
    * Active urinary sediment (\>5 RBCs, \>5 WBCs, or cellular casts)
  * Receiving standard-of-care immunosuppression regimen for active LN, including mycophenolate, cyclophosphamide, belimumab, azathioprine, a calcineurin inhibitor, and/or B cell depleting therapies
  * Recent or ongoing glucocorticoids use for active LN within the past 6 months
  * Receiving standard-of-care antimalarial therapy and RAAS blockade, unless contraindicated
  * Estimated ≥0.5 g/g 24 hr proteinuria or ≥0.3 mg/g 24 hr microalbuminuria at enrollment (on first morning urine)
  * Ability to given informed consent

Exclusion Criteria:

* GFR \< 25 ml/min/1.73m2

  * Acute kidney injury at study enrollment (\>50 percent rise in creatinine within 90 days)
  * Type I diabetes, underweight (BMI \<18.5), active malignancy, active infection, or recurrent genitourinary infections
  * For females: pregnancy, or desiring of pregnancy and not using contraception, or unable to use contraception
  * Current use of \>1mg/kg/day prednisone equivalent
  * Current or prior use of SGLT2 inhibitors or GLP-1 receptor agonists

Conditions2

LupusLupus Nephritis (LN)

Interventions1

Locations2 sites

Massachusetts General Hospital
April M. Jorge, MD617-643-9624amjorge@mgh.harvard.edu
Brigham and Women's Hospital
Karen H. Costenbader, MD, MPH617-732-6088KCostenbader@bwh.harvard.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.